Learn About Sertoli-Leydig Cell Tumor

What is the definition of Sertoli-Leydig Cell Tumor?

Sertoli-Leydig cell tumor (SLCT) is a rare cancer of the ovaries. The cancer cells produce and release a male sex hormone called testosterone.

What are the alternative names for Sertoli-Leydig Cell Tumor?

Sertoli-stromal cell tumor; Arrhenoblastoma; Androblastoma; Ovarian cancer - Sertoli-Leydig cell tumor

What are the causes of Sertoli-Leydig Cell Tumor?

The exact cause of this tumor is not known. Changes (alterations) in genes may play a role.

SLCT occur most often in young women 20 to 30 years old. But the tumor can occur at any age.

What are the symptoms of Sertoli-Leydig Cell Tumor?

The Sertoli cells are normally located in the male reproductive glands (the testes). They feed sperm cells. The Leydig cells, also located in the testes, release a male sex hormone.

These cells are also found in a woman's ovaries, and in very rare cases lead to cancer. SLCT starts in the female ovaries, mostly in one ovary. The cancer cells release a male sex hormone. As a result, the woman may develop symptoms such as:

  • A deep voice
  • Enlarged clitoris
  • Facial hair
  • Loss in breast size
  • Stopping of menstrual periods

Pain in the lower belly (pelvic area) is another symptom. It occurs due to the tumor pressing on nearby structures.

Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Sertoli-Leydig Cell Tumor?

Surgery is done to remove one or both ovaries.

If the tumor is at an advanced stage, chemotherapy or radiation therapy may be done after surgery.

Who are the top Sertoli-Leydig Cell Tumor Local Doctors?
Distinguished in Sertoli-Leydig Cell Tumor
Gynecologic Oncology | Obstetrics and Gynecology | Orthopedics
Distinguished in Sertoli-Leydig Cell Tumor
Gynecologic Oncology | Obstetrics and Gynecology | Orthopedics

Oklahoma Cancer Specialists And Research Institute, LLC

12697 E 51st St, 
Tulsa, OK 
 (38.2 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Katherine Moxley is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Tulsa, Oklahoma. Dr. Moxley and is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Vulvar Cancer, Hysterectomy, and Gastrostomy. Dr. Moxley is currently accepting new patients.

Robert S. Mannel
Distinguished in Sertoli-Leydig Cell Tumor
Gynecologic Oncology | Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Gynecologic Oncology | Oncology

Ou Health Partners Inc

800 Ne 10th St, Ouhp Stephenson Cancer Center, 
Oklahoma City, OK 
 (81.6 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Robert Mannel is a Gynecologic Oncologist and an Oncologist in Oklahoma City, Oklahoma. Dr. Mannel and is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Lymphadenectomy, and Hysterectomy. Dr. Mannel is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Sertoli-Leydig Cell Tumor
Hematology Oncology | Oncology | Hematology
Experienced in Sertoli-Leydig Cell Tumor
Hematology Oncology | Oncology | Hematology

Ou Health Partners Inc

800 Ne 10th St, Ouhp Stephenson Cancer Center, 
Oklahoma City, OK 
 (81.6 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Susanna Ulahannan is a Hematologist Oncology specialist and an Oncologist in Oklahoma City, Oklahoma. Dr. Ulahannan and is rated as an Experienced provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, Breast Cancer, and Bone Marrow Aspiration. Dr. Ulahannan is currently accepting new patients.

What is the outlook (prognosis) for Sertoli-Leydig Cell Tumor?

Early treatment results in a good outcome. Feminine characteristics usually return after surgery. But male characteristics resolve more slowly.

For more advanced stage tumors, outlook is less positive.

What are the latest Sertoli-Leydig Cell Tumor Clinical Trials?
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Summary: This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Background: - Pleuropulmonary blastoma (PPB) is a rare fast-growing lung tumor that is associated with other, rare tumor types. Most cases of PPB appear in children younger than 6 years of age. Recently, it has been shown that this condition can be inherited (e.g., mutation of the DICER1 gene). Researchers are studying both clinical and genetic aspects of this newly described condition. They are interested in...

Who are the sources who wrote this article ?

Published Date: June 17, 2024
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Beffa LB, Sung CJ, DiSilvestro PA. Germ cell, stromal, and other ovarian tumors. In: Creasman WT, Mutch DG, Mannel RS, Tewari KS, eds. DiSaia and Creasman Clinical Gynecologic Oncology. 10th ed. Philadelphia, PA: Elsevier; 2023:chap 10.

Fletcher CDM. Tumors of the female genital tract. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 5th ed. Philadelphia, PA: Elsevier; 2021:chap 13.

Smith RP. Sertoli-Leydig cell tumor (arrhenoblastoma). In: Smith RP, ed. Netter's Obstetrics & Gynecology. 4th ed. Philadelphia, PA: Elsevier; 2024:chap 165.